Abstract
Besides its role as an essential regulator of physiologic and pathologic angiogenesis, vascular endothelial growth factor (VEGF) triggers growth, survival, and migration of leukemia and multiple myeloma cells; plays a pivotal role in hematopoiesis; inhibits maturation of dendritic cells; and increases osteoclastic bone-resorbing activity as well as osteoclast chemotaxis. Dysregulation of VEGF expression and signaling pathways therefore plays an important role in the pathogenesis and clinical features of hematologic malignancies, in particular multiple myeloma. Direct and indirect targeting of VEGF and its receptors therefore may provide a potent novel therapeutic approach to overcome resistance to therapies and thereby improve patient outcome.
| Original language | English |
|---|---|
| Pages (from-to) | 1383-1395 |
| Number of pages | 13 |
| Journal | Blood |
| Volume | 105 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 15 Feb 2005 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Animals
- Hematologic Neoplasms/blood
- Humans
- Neovascularization, Pathologic/blood
- Vascular Endothelial Growth Factor A/biosynthesis
Fingerprint
Dive into the research topics of 'The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver